State Street Corp lessened its position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 7.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,974,429 shares of the biopharmaceutical company’s stock after selling 342,787 shares during the quarter. State Street Corp owned approximately 2.91% of Achillion Pharmaceuticals worth $18,243,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in ACHN. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Achillion Pharmaceuticals by 3.6% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 800 shares during the period. SG Americas Securities LLC boosted its stake in shares of Achillion Pharmaceuticals by 18.6% during the 2nd quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 4,144 shares during the period. TradeLink Capital LLC bought a new position in shares of Achillion Pharmaceuticals during the 2nd quarter worth approximately $132,000. Legal & General Group Plc lifted its holdings in Achillion Pharmaceuticals by 53.8% during the 2nd quarter. Legal & General Group Plc now owns 42,900 shares of the biopharmaceutical company’s stock worth $196,000 after purchasing an additional 15,000 shares during the last quarter. Finally, UBS Asset Management Americas Inc. lifted its holdings in Achillion Pharmaceuticals by 83.8% during the 1st quarter. UBS Asset Management Americas Inc. now owns 53,669 shares of the biopharmaceutical company’s stock worth $226,000 after purchasing an additional 24,471 shares during the last quarter. 76.93% of the stock is currently owned by institutional investors and hedge funds.
In related news, major shareholder & Johnson Johnson sold 18,367,346 shares of the company’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $2.75, for a total transaction of $50,510,201.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 7.24% of the stock is owned by corporate insiders.
Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) traded down $0.03 during mid-day trading on Monday, reaching $2.99. The company had a trading volume of 5,466,168 shares, compared to its average volume of 1,687,054. Achillion Pharmaceuticals, Inc. has a twelve month low of $2.92 and a twelve month high of $5.66.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. During the same period in the prior year, the business posted ($0.15) earnings per share. analysts forecast that Achillion Pharmaceuticals, Inc. will post -0.63 earnings per share for the current fiscal year.
Several analysts recently weighed in on the company. Zacks Investment Research raised Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a report on Monday, November 13th. Chardan Capital reaffirmed a “neutral” rating on shares of Achillion Pharmaceuticals in a report on Sunday, September 17th. Ladenburg Thalmann Financial Services dropped their price objective on Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating for the company in a report on Tuesday, September 12th. Robert W. Baird reaffirmed a “neutral” rating and issued a $4.00 price objective (down from $5.00) on shares of Achillion Pharmaceuticals in a report on Tuesday, September 12th. Finally, ValuEngine cut Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Monday, September 11th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $5.29.
WARNING: “State Street Corp Reduces Position in Achillion Pharmaceuticals, Inc. (ACHN)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/12/04/state-street-corp-reduces-holdings-in-achillion-pharmaceuticals-inc-achn.html.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.